


## $\alpha$ -Amylase/ $\alpha$ -Glucosidase-IN-10

<b>Cat. No.:</b>	HY-162373
<b>Molecular Formula:</b>	C <sub>33</sub> H <sub>40</sub> ClN <sub>5</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	622.15
<b>Target:</b>	Amylases; Glucosidase; P-glycoprotein
<b>Pathway:</b>	Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	$\alpha$ -Amylase/ $\alpha$ -Glucosidase-IN-10 (compound 5d) is an $\alpha$ -amylase and $\alpha$ -glucosidase inhibitor (IC <sub>50</sub> : 30.39 $\mu$ M and 65.1 $\mu$ M) with potential diabetes inhibitory effects. $\alpha$ -Amylase/ $\alpha$ -Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While $\alpha$ -Amylase/ $\alpha$ -Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 30.39 $\mu$ M ( $\alpha$ -Amylase); 65.1 $\mu$ M ( $\alpha$ -Glucosidase)[1]

### REFERENCES

[1]. Ghannay S, et al. Identification of dual-target isoxazolidine-isatin hybrids with antidiabetic potential: Design, synthesis, in vitro and multiscale molecular modeling approaches. Heliyon. 2024 Feb 11;10(4):e25911.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA